trial

Pilot Study of Pregnenolone Augmentation Targeting Cognitive Symptoms in Persistently Symptomatic Patients With Schizophrenia

NCTId NCT00560937
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
— · Completed
Enrollment 28 (actual)
Sponsored by Durham VA Medical Center
Primary completion 2006-04
Synthesized from structured facts only — each point cited above.

Design & status

Phase
—
Status
Completed
Enrollment
28 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2005-06
Primary completion
2006-04
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
Pregnenolone

Sponsors

Durham VA Medical CenterLead Sponsor

Investigators

1
Christine E Marx, MD, MAPrincipal Investigator

Sites

1 total
Durham, United States

Facts & assertions

4 sourced
Enrollment
28
Phase
NA
Primary Completion Date
2006-04
Status
COMPLETED
relationships
The graph out of here
drug
Pregnenolone
drug
lead_sponsor
Durham VA Medical Center
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Christine E Marx, MD, MA
person